Navigation Links
Acclarent, Inc. Awarded 'Red Herring 100 North America'
Date:5/28/2009

MENLO PARK, Calif., May 29 /PRNewswire/ -- Acclarent, Inc., a leading medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat today announced that it won the "Red Herring 100 North America" award. The Red Herring editorial team deploys a detailed process to whittle down a pool of 1,200 eligible, promising companies to decide on the top 100 winners of this important North American award. Evaluations are made on both quantitative and qualitative criteria, such as financial performance, innovation, management, global strategy, and ecosystem integration. Alex Vieux, CEO of Red Herring, presented the award to the winning companies in San Diego on May 14, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090529/LA24185LOGO)

"Acclarent will cure and help millions of Americans over the years. This represents innovation excellence at its best led by pristine investors and a seasoned team. It fully deserves its place within the Red Herring 100 North America," said Mr. Vieux.

"Being recognized by Red Herring as one of the most promising private companies in North America is a tremendous accomplishment. On behalf of the 300 deserving employees at Acclarent, I would like to thank Red Herring for this prestigious award," said Bill Facteau, President and CEO of Acclarent, Inc.

About Red Herring

Red Herring is a global media company, which unites the world's best high technology innovators, venture investors and business decision makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters and major events for technology leaders around the globe. Red Herring provides an insider's access to the global innovation economy, featuring unparalleled insights on the emerging technologies driving the economy. More information about Red Herring is available online at www.redherring.com.

About Acclarent

Acclarent is a medical technology company dedicated to the development of innovative products providing new technologies to further meet the needs of ENT patients.

Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices. Through the Balloon Sinuplasty(TM) technology and our Relieva(R) product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT. Acclarent markets and sells its products worldwide and has been used by thousands of physicians globally. For more information about Acclarent, visit www.Acclarent.com.


'/>"/>
SOURCE Red Herring
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies
2. Acclarent, Inc. Closes $26 Million Financing
3. Concurrent Technologies Corporation Awarded Contract to Support the Centers for Disease Control and Prevention with Readiness Efforts
4. Falcon Genomics Awarded Patent for Innovative Cancer Test
5. $18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research
6. MHA Clinical Director Kimberly Binaso, Pharm.D. Awarded 2009 ASHP Fellow
7. University of Haifa research team awarded European Union research grant
8. $1.5 million awarded for palliative care research to improve care of seriously ill patients
9. NCQA Accreditation Status of Excellence Awarded to Blue Cross and Blue Shield of Georgia
10. MiP Consortium awarded €11 million by EDCTP
11. American Cancer Society Awarded Dual WellPoint Foundation Grants to Expand Hope Lodge Network and Patient Navigation Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 2017 , ... An August 3rd article on Reuters covers a new University of ... JAMA (the Journal of the American Medical Association). The study found that a lower percentage ... 30, when compared to patients with lower BMIs. At present, weight loss patients must have ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... In ... They celebrate 30 years in business this year, and they’re marking the milestone ... space to serve their patients. , It stands to reason that, given ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... ... Paul Vitenas, MD, FACS , is honored to announce that he ... the nation’s top physicians, in a variety of specialties. This marks the fourth year ... Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of information on ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology: